Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

NCT03382977 is registered in ClinicalTrials.gov with VBI Vaccines Inc. as lead sponsor.

NCT NCT03382977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03382977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects
Lead sponsor
VBI Vaccines Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 6, 2017
Completion date
August 30, 2025
Enrollment
70 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme